The first in vivo CRISPR-Cas9 gene editing therapy, lonvoguran ziclumeran (lonvo-z), is expected to receive US FDA approval in 2027 for hereditary angioedema.
What is the First In Vivo CRISPR-Cas9 Gene Editing Therapy?
The first in vivo CRISPR-Cas9 therapy is lonvoguran ziclumeran (lonvo-z), developed by Intellia Therapeutics. Unlike earlier CRISPR treatments that edit cells outside the body (ex vivo), lonvo-z is administered as a single intravenous infusion. It uses lipid nanoparticles to deliver Cas9 mRNA and a guide RNA directly to the patient's liver cells, permanently disabling the KLKB1 gene. This approach treats hereditary angioedema (HAE) by reducing attacks without repeated dosing.
When Will Lonvo-z Receive FDA Approval?
According to Intellia's public statements and the HAELO Phase 3 trial results announced in April 2026, lonvo-z is expected to receive FDA Biologics License Application (BLA) approval in the first half of 2027. The company initiated a rolling BLA submission in April 2026, with completion planned for the second half of 2026. Intellia targets commercial launch in H1 2027. The FDA approval timeline is based on priority review, though no formal FDA action date has been set.
What Did the HAELO Phase 3 Trial Show?
The HAELO Phase 3 study enrolled 80 patients with hereditary angioedema. Results announced in April 2026 demonstrated that a single 50 mg intravenous dose of lonvo-z reduced angioedema attacks by 87% compared to placebo over a six-month evaluation period. All key secondary endpoints were met with statistical significance. This efficacy profile supports the therapy's value proposition as a one-time, durable solution for HAE, which currently requires lifelong prophylactic treatment.
How Does Lonvo-z Differ from Casgevy and Other CRISPR Therapies?
Casgevy, approved in 2023, uses ex vivo CRISPR editing: cells are removed from the patient, edited in a lab, and reinfused. Lonvo-z is fundamentally different. It performs gene editing entirely inside the living human body. The lipid nanoparticle formulation targets hepatocytes specifically, and the guide RNA directs Cas9 to the KLKB1 gene. This in vivo approach eliminates the need for conditioning chemotherapy or cell transplantation, making it less invasive and potentially safer for broader patient populations.
What Are the Safety Risks of In Vivo CRISPR Editing?
The primary safety signal monitored in this class is liver enzyme elevation, indicating potential hepatocyte stress. For Intellia's other CRISPR candidate, nex-z, the FDA placed two Phase 3 trials on clinical hold in October 2025 due to safety concerns. The hold was lifted in March 2026 after Intellia provided additional data. For lonvo-z, no serious liver-related adverse events have been reported in published trial data, but ongoing monitoring is required. Intellia's safety database includes long-term follow-up from earlier Phase 1/2 studies.
What Is the Regulatory Pathway for Lonvo-z at the FDA?
Lonvo-z is regulated as a biologic, requiring a Biologics License Application (BLA). Intellia initiated a rolling BLA submission in April 2026, allowing FDA to review sections as they are completed. The submission includes chemistry, manufacturing, and controls (CMC) data, nonclinical toxicology, and clinical efficacy/safety results from HAELO. Given the breakthrough therapy designation and priority review eligibility, FDA action could occur within 6-8 months of complete submission, aligning with an H1 2027 approval.
What Are the Commercial Launch Plans for Lonvo-z?
Intellia has stated its target for commercial launch in the first half of 2027. Manufacturing will utilize lipid nanoparticle production at Intellia's own facilities, with scale-up capabilities for global distribution. Pricing is not yet disclosed, but analysts estimate a one-time cost between $500,000 and $1 million, reflecting its curative potential versus chronic therapy costs. Reimbursement strategies include outcomes-based contracts with payers.
Frequently Asked Questions
Q1: How long does the effect of lonvo-z last?
Based on the HAELO Phase 3 trial, the 87% attack reduction was measured over six months post-dose. Intellia's earlier Phase 1/2 data show durable gene editing and clinical response for over two years in some patients. Since the KLKB1 gene is permanently inactivated in liver cells, the therapeutic effect is expected to be lifelong, though long-term follow-up studies are ongoing.
Q2: Who is eligible for lonvo-z treatment?
Eligibility criteria from clinical trials include adults with a confirmed diagnosis of hereditary angioedema type I or II, experiencing at least two attacks per month despite standard prophylaxis. Patients with significant liver disease or prior gene therapy exposure were excluded. The FDA label will specify exact indications, but Intellia aims to position lonvo-z for all HAE patients who have failed or are intolerant to existing prophylactic treatments.
Q3: What is the source of the clinical data cited in this article?
The primary source is Intellia Therapeutics' press release dated April 2026, announcing HAELO Phase 3 top-line results. Additional data come from the FDA's clinical hold and lift notices for nex-z (October 2025 and March 2026, respectively), as published in the Federal Register and Intellia's SEC filings. The Casgevy approval details are from FDA's 2023 approval announcement. All sources are publicly available via Intellia's investor relations page and FDA.gov.